AusperBio Therapeutics

New Capabilities

Developing AHB-137 as an investigational hepatitis B therapy

For most people with chronic hepatitis B, daily antiviral pills suppress the virus but do not clear it. A small follow-up study now reports that an experimental antisense oligonucleotide, AHB-137, kept the virus undetectable in some participants for up to 15 months after every hepatitis B treatment stopped. The study defines functional cure as hepatitis B surface antigen below 0.05 IU/mL and HBV DNA below 10 IU/mL for at least 24 weeks without treatment.

Updated 3 hours ago